Physician profile
Rina Rosa Roginsky
NPI 1821189390
$3,374.60
in general payments reported to CMS, 2019-2025
35 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $138 · 2021: $189 · 2022: $1,289 · 2023: $603 · 2024: $352 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.13 |
| Education | $125.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.83 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Aspira Women'S Health INC | $343.76 | 2021-2023 | Ova1 |
| Astellas Pharma US INC | $256.03 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $197.06 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $187.36 | 2022-2025 | |
| Mylan Pharmaceuticals INC. | $162.49 | 2019-2022 | |
| Organon LLC | $156.69 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $124.46 | 2021-2025 | Slynd |
| Evofem Biosciences, INC. | $122.14 | 2021-2025 | Solosec, Phexx, Phexxi |
| Daiichi Sankyo INC. | $115.68 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $112.96 | 2019-2023 | |
| Millicent US INC | $99.19 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $94.86 | 2022 | |
| Channel Medsystems, INC. | $87.22 | 2022 | |
| Shield Therapeutics INC | $83.92 | 2023-2025 | Accrufer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $68.88 | 2019 | |
| Sage Therapeutics, LLC | $65.53 | 2023-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $64.46 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $57.33 | 2023 | Myfembree, Gemtesa |
| Smith+Nephew, INC. | $57.20 | 2022-2025 | Stravix Pl |
| Scynexis, INC. | $50.90 | 2022 | |
| Myovant Sciences INC. | $40.92 | 2022 | |
| Avion Pharmaceuticals | $37.41 | 2019-2020 | |
| Urovant Sciences INC | $35.01 | 2022 | |
| Welch Allyn | $32.94 | 2019 | |
| Hologic Sales and Service, LLC | $32.55 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $25.20 | 2019-2020 | |
| Ethicon US, LLC | $19.11 | 2020 | |
| Medtronic, INC. | $17.45 | 2023 | Endo Stitch |
| Vertical Pharmaceuticals, LLC | $17.30 | 2019 | |
| Novo Nordisk INC | $16.96 | 2023 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $16.90 | 2023 | Seglentis |
| Coopersurgical, INC. | $14.44 | 2024 | Paragard T 380a |
| Duchesnay USA Incorporated | $11.67 | 2019 | |
| Allergan, INC. | $9.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Roginsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.